JHEP reports : innovation in hepatology · 2026
Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kah Janine, Staffeldt Lisa, Stefanski Svenja, Herzog Natalie, Mattert Gregor, Volz Tassilo, Voß Maximilian, Schulze Kornelius, Heumann Asmus, Dammermann Werner, Kammerer Sarah, Küpper Jan-Heiner, Villavicencio-Lorini Pablo, Dandri Maura, Lüth Stefan
Аннотация
BACKGROUND & AIMS: HBV-associated hepatocellular carcinoma (HCC) is characterized by immune evasion and heterogeneous responses to immunotherapy. However, the mechanisms driving tumor-immune tolerance and their impact on checkpoint inhibitor-based therapies remain poorly understood. To address this gap, we generated a patient-derived HBV-induced HCC cell line that preserves a clinically relevant immune evasion mechanism mediated by human leukocyte antigen G (HLA-G) expression.
METHODS: We performed whole-exome sequencing on two spatially separated tumor regions to define genomic signatures with emphasis on the HLA-G locus. Patient-derived tumor cells were modified using upcyte® technology, generating the up-LC14A1 cell line. Molecular stratification included an in-house HCC cohort (n = 13), healthy donors (n = 4), serum samples from early-stage liver disease (n = 4), diagnosed HCC (n = 10), and global datasets (TCGA biopsies, n = 24; HCC, n = 120). Functional characterization included NK92 co-culture assays (1:1, 1:5, 1:10) and orthotopic transplantation in mice (HUH7, n = 3; Hep3B, n = 4; HepG2H1.3, n = 4; up-LC14A1, n = 14).
RESULTS: Whole-exome sequencing revealed a clonally coherent HCC carrying an HLA-G 3'UTR haplotype associated with immune tolerance. Cohort stratification confirmed elevated soluble HLA-G in patient #14. The derived up-LC14A1 line retained hepatobiliary and viral features and showed stable proliferation with low-level HBV DNA production. Transcriptomic profiling positioned up-LC14A1 within the HCC landscape. In vivo, orthotopic transplantation generated structured liver tumors and prolonged survival compared with immortalized HCC lines. The up-LC14A1 cell line resisted NK92 cytotoxicity through dynamic HLA-G induction, while HLA-G silencing restored immune killing and induced compensatory PD-L1 expression.
CONCLUSIONS: The up-LC14A1 model represents a patient-derived HBV-HCC system capturing a clonally stable but dynamically regulated HLA-G-mediated immune-tolerant state. This platform enables mechanistic investigation of immune escape and provides a translational model for testing targeted immunotherapies in HBV-associated HCC.
IMPACT AND IMPLICATIONS: HBV-associated HCC exhibits a profound immune evasion capacity and an insufficient response to immunotherapy. Nevertheless, preclinical models that mimic viral persistence and tumor resistance are underrepresented. The immune modulatory molecule HLA-G has emerged as a potent target for immunotherapy in HCCs owing to its direct suppression of T and NK cells. Here, we established a novel patient-derived HBV-HCC cell line (up-LC14A1) that mediates immune evasion via HLA-G upregulation.
METHODS: We performed whole-exome sequencing on two spatially separated tumor regions to define genomic signatures with emphasis on the HLA-G locus. Patient-derived tumor cells were modified using upcyte® technology, generating the up-LC14A1 cell line. Molecular stratification included an in-house HCC cohort (n = 13), healthy donors (n = 4), serum samples from early-stage liver disease (n = 4), diagnosed HCC (n = 10), and global datasets (TCGA biopsies, n = 24; HCC, n = 120). Functional characterization included NK92 co-culture assays (1:1, 1:5, 1:10) and orthotopic transplantation in mice (HUH7, n = 3; Hep3B, n = 4; HepG2H1.3, n = 4; up-LC14A1, n = 14).
RESULTS: Whole-exome sequencing revealed a clonally coherent HCC carrying an HLA-G 3'UTR haplotype associated with immune tolerance. Cohort stratification confirmed elevated soluble HLA-G in patient #14. The derived up-LC14A1 line retained hepatobiliary and viral features and showed stable proliferation with low-level HBV DNA production. Transcriptomic profiling positioned up-LC14A1 within the HCC landscape. In vivo, orthotopic transplantation generated structured liver tumors and prolonged survival compared with immortalized HCC lines. The up-LC14A1 cell line resisted NK92 cytotoxicity through dynamic HLA-G induction, while HLA-G silencing restored immune killing and induced compensatory PD-L1 expression.
CONCLUSIONS: The up-LC14A1 model represents a patient-derived HBV-HCC system capturing a clonally stable but dynamically regulated HLA-G-mediated immune-tolerant state. This platform enables mechanistic investigation of immune escape and provides a translational model for testing targeted immunotherapies in HBV-associated HCC.
IMPACT AND IMPLICATIONS: HBV-associated HCC exhibits a profound immune evasion capacity and an insufficient response to immunotherapy. Nevertheless, preclinical models that mimic viral persistence and tumor resistance are underrepresented. The immune modulatory molecule HLA-G has emerged as a potent target for immunotherapy in HCCs owing to its direct suppression of T and NK cells. Here, we established a novel patient-derived HBV-HCC cell line (up-LC14A1) that mediates immune evasion via HLA-G upregulation.